Guggenheim downgraded Incyte (INCY) to Neutral from Buy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s Promising Phase 3 Results and Market Potential Drive Buy Rating
- Leerink says Incyte’s povo trial results disappoint, drug likely to be approved
- PepsiCo to acquire poppi, Guess receives WHP offer: Morning Buzz
- Incyte stock decline after results an ‘overreaction,” says Wolfe Research
- Incyte could see some weakness as povo looks mostly as expected, RBC says